Clopidogrel
Product Images NDC 68645-430

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 68645-430). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Legacy Pharmaceutical Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula For Clopidogrel Bisulfate (Clopidogrel Tablets Usp 1)

Chemical structure diagram of Clopidogrel, illustrating its molecular composition including a thiophene ring, a chlorophenyl group, and its sulfate salt form.*

FDA Label Image

Clopidogrel Tablets Usp 75mg (Clopidogrel Tablets Usp 10)

Clopidogrel Tablets, USP 75 mg oral tablet label, with a quantity of 30 tablets. The label shows the active ingredient amount as 75 mg, with instructions to see accompanying drug information. Distributed by Wal-Mart, manufactured by Teva Pharmaceuticals USA, and packaged by Legacy Pharmaceutical Packaging LLC in Earth City, MO.*

FDA Label Image

Figure 1 (Clopidogrel Tablets Usp 2)

A horizontal error bar chart showing the effect of coadministered proton pump inhibitors (PPIs) on the active metabolite AUC of clopidogrel. It compares four PPIs (Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, Omeprazole 80 mg) with mean and 90% confidence intervals, illustrating changes relative to clopidogrel administered alone.*

FDA Label Image

Figure 2 (Clopidogrel Tablets Usp 3)

A line graph showing cumulative event rates (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up comparing Clopidogrel (+ aspirin) versus placebo (+ aspirin). The graph indicates lower event rates for Clopidogrel with aspirin compared to placebo with aspirin.*

FDA Label Image

Figure 3 (Clopidogrel Tablets Usp 4)

A forest plot chart illustrating hazard ratios comparing Clopidogrel versus placebo across various baseline characteristics and concomitant medications. The chart includes groups such as diagnosis, age, gender, race, diabetes status, prior myocardial infarction, and concurrent therapies like aspirin and beta-blockers, displaying percent events and confidence intervals with a vertical reference line for neutral effect.*

FDA Label Image

Figure 3: Cumulative Event Rates For Death In The Commit Study (Clopidogrel Tablets Usp 5)

A Kaplan-Meier survival curve graph showing the percentage of deaths before first discharge over 28 days since randomization. Two curves compare Placebo and Clopidogrel with respective death counts and percentages, highlighting a 7% proportional risk reduction for Clopidogrel (p = 0.03).*

FDA Label Image

Figure 5 (Clopidogrel Tablets Usp 6)

A line graph comparing the percentage of patients with death, re-infarction, or stroke before first discharge over 28 days between placebo and Clopidogrel groups. The graph shows a lower event rate for Clopidogrel (9.2%) compared to placebo (10.1%), indicating a 9% proportional risk reduction with statistical significance (p = 0.002).*

FDA Label Image

Figure 6 (Clopidogrel Tablets Usp 7)

A forest plot chart comparing event percentages and odds ratios with confidence intervals for Clopidogrel versus placebo across multiple baseline categories like sex, age, blood pressure, heart rate, and treatment conditions. The chart includes heterogeneity tests and confidence intervals, displaying proportional reduction and statistical values.*

FDA Label Image

Figure 7 (Clopidogrel Tablets Usp 8)

A forest plot chart showing event percentages and odds ratios comparing Clopidogrel and Placebo in patient subgroups based on Killip class, previous myocardial infarction, and infarct location. The chart includes proportional reduction and confidence intervals illustrating Clopidogrel's effect with statistical measures of heterogeneity and significance values noted.*

FDA Label Image

Figure 8 (Clopidogrel Tablets Usp 9)

A line graph showing the cumulative event rate percentage of fatal or non-fatal vascular events over 36 months of follow-up, comparing two groups labeled Aspirin and Clopidogrel. The graph indicates a difference in event rates over time, with a p-value of 0.045 reported.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.